Sugi Predict

Sugi Predict / Compounds / SCHEMBL18152630

SCHEMBL18152630

SCHEMBL18152630

Cc1ccc2n(c1=O)CCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.38
▸ HPGD P15428 4/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ USP2 O75604 2/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ KDM4E B2RXH2 5/20 0.35
▸ GAA P10253 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ KMT2A Q03164 3/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ CFTR P13569 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ HKDC1 Q2TB90 1/20 0.34
▸ GOPC Q9HD26 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29161593 0.94 ALDH1A1 (0.38) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL29161623 0.92 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL29200211 0.78 KDM4E (0.35) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL22017086 0.77 ALOX5 (0.38) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL15742528 0.76 ALDH1A1 (0.34) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL22016195 0.76 SMN1; SMN2 (0.32) ALDH1A1HSD17B10USP2SMN1; SMN2KDM4E
SCHEMBL22016184 0.76 TLR8 (0.32) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL9665568 0.76 ALDH1A1 (0.35) ALDH1A1HPGDHSD17B10USP2SMN1; SMN2
SCHEMBL18473713 0.73 PDE3B (0.39) ALDH1A1HPGDHSD17B10USP2KMT2A
SCHEMBL23888686 0.72 ALDH1A1 (0.38) ALDH1A1HPGDHSD17B10USP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041518-A1 QUINOLINE DERIVATIVES GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-30 — — US disclosed
US-11116760-B2 Quinoline derivatives GILEAD SCIENCES, INC. (US) 2021-09-14 — — US disclosed
EP-3831383-A1 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-06-09 — — EP disclosed
EP-3831383-A1 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-06-09 — — EP disclosed
EP-3283077-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2021-03-10 — — EP disclosed
EP-3283077-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2021-03-10 — — EP disclosed
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-04 — — US disclosed
US-10807982-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-20 — — US disclosed
US-10807982-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-20 — — US disclosed
US-20180134710-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-05-17 — — US disclosed
US-9908885-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-03-06 — — US disclosed
US-9908885-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-03-06 — — US disclosed
US-9908885-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-03-06 — — US disclosed
EP-3283077-A2 BROMODOMAIN INHIBITOR Celgene Quanticel Research, Inc. (US) 2018-02-21 — — EP disclosed
US-20170050968-A1 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. 2017-02-23 — — US disclosed
US-20170050968-A1 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. 2017-02-23 — — US disclosed
US-20170050968-A1 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. 2017-02-23 — — US disclosed
WO-2016168682-A2 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. (US) 2016-10-20 — — WO disclosed
WO-2016168682-A2 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. (US) 2016-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS MAP3K14, NFKBIA, MAP3K15 ALDH1A1 4311/4885HPGD 1086/4885HSD17B10 1444/4885
US-20230041518-A1 QUINOLINE DERIVATIVES CFTR, NQO1, IRF3 ALDH1A1 476/4885HPGD 585/4885HSD17B10 1037/4885
US-20170050968-A1 BROMODOMAIN INHIBITOR BRD3, BRPF3, EP300 ALDH1A1 3261/4885HPGD 1327/4885HSD17B10 2411/4885
US-10807982-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885HSD17B10 2477/4885
US-20180134710-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885HSD17B10 2477/4885
US-11116760-B2 Quinoline derivatives CFTR, NQO1, IRF3 ALDH1A1 476/4885HPGD 585/4885HSD17B10 1037/4885
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors MAP3K14, NFKBIA, MAP3K15 ALDH1A1 4311/4885HPGD 1086/4885HSD17B10 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.